JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (7): 45-49.doi: 10.6040/j.issn.1671-7554.0.2013.750
Previous Articles Next Articles
LI Yueyue, ZUO Xiuli, JI Rui, CHEN Feixue, ZHAO Hongyu, WANG Han, GUO Jing, ZHANG Jingyuan, FU Shanshan, LIU Jianwei, LI Yanqing
CLC Number:
[1] McColl K E. Clinical practice. Helicobacter pylori infection[J]. N Engl J Med, 2010, 362(17):1597-1604. [2] Suerbaum S, Michetti P. Helicobacter pylori infection[J]. N Engl J Med, 2002, 347(15):1175-1186. [3] Hopkins R J, Girardi L S, Turney E A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review[J]. Gastroenterology, 1996, 110(4):1244-1252. [4] Graham D Y, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance[J]. Gut, 2010, 59(8):1143-1153. [5] Malfertheiner P, Megraud F, O'Morain C A, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report[J]. Gut, 2012, 61(5):646-664. [6] Georgopoulos S D, Xirouchakis E, Martinez-Gonzalez B, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of helicobacter pylori in a high clarithromycin resistance area[J]. Helicobacter, 2013, 18(6):459-467. [7] Huang Y K, Wu M C, Wang S S, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication[J]. J Dig Dis, 2012, 13(4):232-238. [8] Lim J H, Lee D H, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study[J]. Helicobacter, 2013, 18(3):180-186. [9] Yang Y J, Sheu B S. Sequential therapy in childhood Helicobacter pylori eradication: emphasis on drug compliance[J]. J Pediatr, 2011, 159(4):700. [10] Lee M, Kemp J A, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy[J]. Arch Intern Med, 1999, 159(19):2312-2316. [11] Manfredi M, Bizzarri B, Sacchero R I, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy[J]. Helicobacter, 2012, 17(4):254-263. [12] Kadayifci A, Uygun A, Polat Z, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori[J]. Turk J Gastroenterol, 2012, 23(1):8-13. [13] 刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].胃肠病学, 2012, 51(10):618-625. [14] Malfenheiner P, Bazzoli F, Delchier J C, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-1abel, non-inferiority, phase 3 trial[J]. Lancet, 2011, 377(9769):905-913. [15] Zheng Q, Chen W J, Lu H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance[J]. J Dig Dis, 2010,11(5):313-318. [16] Ford A C, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis[J]. World J Gastroenterol, 2008,14(48):7361-7370. [17] Graham D Y, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12(4):275-278. [18] Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy[J]. BMJ, 2013, 347: f4587. doi: 10.1136/bmj.f4587. [19] Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China[J]. Helicobacter, 2013, 18(4):274-279. [20] Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China[J]. Helicobacter, 2010, 15(5):460-466. [21] Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication[J]. Aliment Pharmacol Ther, 2000, 14(12):1639-1643. [22] Romano M, Iovene M R, Montella F, et al. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection[J]. Am J Gastroenterol, 2000, 95(11):3317-3318. [23] Hsu P I, Chen W C, Tsay F W, et al. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for helicobacter pylori infection after failure of sequential therapy[J]. Helicobacter, 2014, 19(1):74-79. [24] Rodríguez-Torres M, Salgado-Mercado R, Ríos-Bedoya C F, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin[J]. Dig Dis Sci, 2005, 50(4):634-639. |
[1] | XU Cui, WANG Tao, ZHOU Ping. Immunohistochemical analysis of Helicobacter pylori infection in children [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 81-84. |
[2] | WANG Hui. Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 52-56. |
[3] | YANG Xue, QIU Chunhua, LEI Lei, HU Xiao. Characteristics of gastric polyps and correlation with helicobacter pylori infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 41-44. |
|